Single combination pill to lower blood pressure, cholesterol, and clotting after a stroke
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II Study
This project tests a low-cost single pill that combines aspirin, a statin, and blood-pressure medicines to help people who have had a stroke in sub-Saharan Africa take their treatments and lower the chance of another stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern California Institute/res/edu NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11375530 on NIH RePORTER |
What this research studies
If you join, you would be offered a single fixed-dose pill that contains aspirin, a cholesterol-lowering drug, and blood-pressure medicines to replace multiple separate pills. Researchers will follow your blood pressure, cholesterol, medication-taking, and any repeat strokes or serious health events over time. The work focuses on stroke survivors in Ghana and aims to make long-term prevention easier in low-resource settings. The team will compare outcomes for people offered the combination pill with those receiving usual care to see if the pill improves adherence and health.
Who could benefit from this research
Good fit: Adults in Ghana or similar sub-Saharan African settings who have survived a stroke and need blood-pressure, cholesterol, and antiplatelet treatment are the intended candidates.
Not a fit: People who have not had a stroke or who cannot take aspirin, statins, or blood-pressure medicines because of allergies or medical contraindications are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could make it easier to take medicines and reduce the risk of another stroke or death.
How similar studies have performed: Similar 'polypill' approaches have improved medication adherence and risk-factor control in other populations, but they are less tested among stroke survivors in sub-Saharan Africa.
Where this research is happening
San Francisco, United States
- Northern California Institute/res/edu — San Francisco, United States (Active)
Researchers
- Principal investigator: Ovbiagele, Bruce — Northern California Institute/res/edu
- Study coordinator: Ovbiagele, Bruce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.